Off the wire
• Felix wins women's 400m gold  • Women's 800 meters semifinal results at athletics worlds  • Women's 200 meters semifinal results at athletics worlds  • Urgent: U.S. economy grows 3.7 pct in Q2: revised data  • Israeli security forces demolish illegal buildings in West Bank  • 1st LD-Writethru-China Focus: Top planner demands hard work for economic targets  • Indonesia's state firms prepare to buy back shares  • Poland's Wlodarczyk wins women's hammer throw gold  • Womens hammer throw final results at athletics worlds  • 1st Ld Writethru: India sends satellite aboard GSLV rocket  
You are here: 　 Home

Novo Nordisk to invest 2 bln USD in new production sites

Xinhua, August 27, 2015 Adjust font size:

Danish pharmaceuticals company Novo Nordisk announced on Thursday it plans to invest an estimated 2 billion U.S. dollars over the next five years in two new production facilities.

One of the production facilities will be located in Clayton, United States, and will produce active pharmaceutical ingredients (API) for the treatment of type 2 diabetes and a range of insulin products, the company said in a statement.

The investment is estimated to create some 700 new production and engineering jobs in Clayton where Novo Nordisk already employs more than 700 people.

The company also plans to establish a new production facility in Maaloev, Denmark, for tableting and packaging of oral semaglutide and future oral products, which is expected to create an estimated 100 new jobs.

"With the new plant in Clayton and continuous investments in our current API production plants in Kalundborg, Denmark, we will have sufficient API capacity for diabetes products well into the next decade," said Henrik Wulff, executive vice president and head of product supply at Novo Nordisk.

He explained that the decision to place the new API facilities in the United States is for strategic reasons as the United States is by far Novo Nordisk's largest market and there are many logistical and economic advantages of having a larger part of the company's manufacturing in the main market.

The two facilities are expected to be operational in 2020. Endit